The TRAIL apoptotic pathway in cancer onset, progression and therapy

被引：714

作者：

Johnstone, Ricky W. ^{[1
]}

Frew, Ailsa J. ^{[1
]}

Smyth, Mark J. ^{[1
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia

来源：

NATURE REVIEWS CANCER | 2008年 / 8卷 / 10期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nrc2465

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triggering of tumour cell apoptosis is the foundation of many cancer therapies. Death receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized, as have the signals that are generated when these receptors are activated. TNF-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility of recombinant TRAIL and agonistic antibodies against TRAILR1 and TRAILR2.

引用

页码：782 / 798

页数：17

共 216 条

[51]

GRECO FA, 2008, LUNG CANC

[52]

Griffith TS, 1999, J IMMUNOL, V162, P2597

[53] Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL [J].

Griffith, TS ;

Wiley, SR ;

Kubin, MZ ;

Sedger, LM ;

Maliszewski, CR ;

Fanger, NA .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (08) :1343-1353

[54] TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development [J].

Grosse-Wilde, Anne ;

Voloshanenko, Oksana ;

Bailey, S. Lawrence ;

Longton, Gary M. ;

Schaefer, Uta ;

Csernok, Andreea I. ;

Schuetz, Guenter ;

Greiner, Erich F. ;

Kemp, Christopher J. ;

Walczak, Henning .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :100-110

[55] Cotreatment with histone deacetylase inhibitor LAQ824 enhances apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells [J].

Guo, F ;

Sigua, C ;

Tao, JG ;

Bali, P ;

George, P ;

Li, YQ ;

Wittmann, S ;

Moscinski, L ;

Atadja, P ;

Bhalla, K .

CANCER RESEARCH, 2004, 64 (07) :2580-2589

[56] Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition [J].

Hallett, William H. D. ;

Ames, Erik ;

Motarjemi, Milad ;

Barao, Isabel ;

Shanker, Anil ;

Tamang, David L. ;

Sayers, Thomas J. ;

Hudig, Dorothy ;

Murphy, William J. .

JOURNAL OF IMMUNOLOGY, 2008, 180 (01) :163-170

[57] 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation [J].

Han, Hoon ;

Shin, Sung-Won ;

Seo, Chi-Yeon ;

Kwon, Hyuk-Chan ;

Han, Jin-Yeong ;

Kim, In-Hoo ;

Kwak, Jong-Young ;

Park, Joo-In .

APOPTOSIS, 2007, 12 (11) :2101-2114

[58] The hallmarks of cancer [J].

Hanahan, D ;

Weinberg, RA .

CELL, 2000, 100 (01) :57-70

[59] Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines [J].

Harada, K ;

Toyooka, S ;

Maitra, A ;

Maruyama, R ;

Toyooka, KO ;

Timmons, CF ;

Tomlinson, GE ;

Mastrangelo, D ;

Hay, RJ ;

Minna, JD ;

Gazdar, AF .

ONCOGENE, 2002, 21 (27) :4345-4349

[60] NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy [J].

Hayakawa, Y ;

Screpanti, V ;

Yagita, H ;

Grandien, A ;

Ljunggren, HG ;

Smyth, MJ ;

Chambers, BJ .

JOURNAL OF IMMUNOLOGY, 2004, 172 (01) :123-129

← 1 2 3 4 5 6 7 8 9 10 →